RareResearch.AI
← Back to atlas

E273K

Category 5 — IDR ExclusionConflictingCytoplasmic · predictedEditorial
GlutamateLysine at position 273 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Glutamate → Lysine at position 273 in N-terminal cytoplasmic domain. ClinVar Conflicting with broad spectrum — Cataract 41, DFNA6. AlphaMissense 0.15 (below threshold) — AM under-call. DynaMut2 ΔΔG +0.25. pLDDT 29 — Category 5 IDR!

Interactive 3D Structure

Wild-type reference
Wild-type E273 — native residue, no strong sidechain contacts
Fullscreen ↗
DynaMut2 mutant · E273K
Mutant K273 — energy-minimized; local contact network preserved
Fullscreen ↗

Computational Predictions

DynaMut2 ΔΔG
0.25kcal/mol
Stabilising — mild
AlphaMissense
0.148
LBen
AlphaFold pLDDT
29
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion
ΔΔG confidence: Reduced confidence · Cytoplasmic
  • pLDDT 28.91 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditionsCataract 41; Autosomal dominant nonsyndromic hearing loss 6 (DFNA6)
InheritanceMulti-phenotype AD.
Population frequency (gnomAD v4)Low frequency · AF 0.010%
cDNA changec.817G>A
ClinVar accessionVCV000215382
Last evaluated2025/12/30 00:00

Observed in the general population.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for Cataract 41 (autosomal dominant, OMIM 116400); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); Wolfram-like syndrome (autosomal dominant, OMIM 614296). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.010% · 165 / 1,612,748 alleles
Homozygotes
0
Highest-frequency population
Admixed American · AF 0.105%

Highest in Admixed American: AF 0.105% (63 of 60,030 alleles), 10.3x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
Admixed American0.105%63 / 60,0300~1 in 480
European (non-Finnish)0.0085%100 / 1,180,0180~1 in 5900
Remaining individuals0.0032%2 / 62,4560~1 in 15610

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position 273 at pLDDT 29 — deep in the IDR region. Sparse neighbor analysis (only sequence neighbors LEU274, ASP272, ALA275 within 5 Å) confirms IDR character. DynaMut2 prediction not trustworthy.

AM 0.15 below threshold. Multi-phenotype clinical evidence (Cataract 41, DFNA6) confirms — but the IDR mechanism is invisible to AM.

Amino-acid chemistry
Glutamate (E) → Lysine (K) — charge reversal.
Position in the protein
N-terminal cytoplasmic domain · position 273 IDR (pLDDT 29 — deep IDR).

Druggability Assessment

Category 5 — IDR Exclusion. pLDDT 29 deep IDR. AlphaMissense 0.15 below threshold. DynaMut2 prediction not trustworthy.

The Atlas routes Category 5 variants to wet-lab characterization. Multi-phenotype confirms clinical pathogenicity — mechanism likely IDR-mediated.

Why this matters

E273K is another deep-IDR Category 5 variant — Atlas appropriately flags.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the E273K PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download E273K PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A